MAY - 7 1998



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Kurt G. Briscoe Sprung Horn Kramer & Woods 660 White Plains Road Tarrytown, New York 10591-5144 In Re: Patent Term Extension
Application for
U.S. Patent No. 4,670,444

## NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,670,444, which claims the animal drug product BAYTRIL® (enrofloxacin) and a method of use of BAYTRIL® (enrofloxacin), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be three years.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue a certificate of extension, under seal, for a period of three years.

The period of extension has been calculated using the Food and Drug Administration determination of the length of the regulatory review period published in the Federal Register of March 18, 1997 (62 Fed. Reg. 12831). Under 35 U.S.C. § 156(c):

Period of Extension = ½ (Testing Phase) + Approval Phase = ½ (648 - 648) + 3,686 - 273

= 3,413 days (9.35 years)

Since the regulatory review period began November 24, 1984, before the patent issued (June 2, 1987), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period. 35 U.S.C. § 156(c). The testing phase of an approved product is defined as the period beginning on the date that an exemption under subsection 512(j) of the Federal Food Drug and Cosmetic Act became effective for the approved product, November 24, 1984, and ending on the date an application for the approved product was initially submitted under subsection 512(b), September 2, 1986. Since both of these dates were before the issue date of the patent, June 2, 1987, none of the testing phase has been considered. The approval phase of a product begins on the date the application for the approved product was initially submitted. For BAYTRIL®, this date was September 2, 1986, which was also before the issue date of the patent, June 2, 1987. Accordingly, since from September 2, 1986 to June 2, 1987 is 273 days, this period is subtracted from the number of days occurring in the approval phase according to the FDA determination of the length of the regulatory review period. No determination of a lack of due diligence under 35 U.S.C.

## § 156(c)(1) was made.

The three year limitation of 35 U.S.C. § 156(g)(6)(C) applies in the present situation because the patent was issued (June 2, 1987) and an action described in 35 U.S.C. § 156(g)(6)(B) was taken (November 24, 1984) before the date of enactment of 35 U.S.C. § 156 with respect to the approved product (November 16, 1988, see 35 U.S.C. § 156(f)(8)). Since the period of extension calculated under 35 U.S.C. § 156(c) for the patent cannot exceed three years under 35 U.S.C. § 156(g)(6)(C), the period of extension will be for three years.

The 14 year limitation of 35 U.S.C. § 156(c)(3) does not operate to further reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:

4,670,444

Granted:

June 2, 1987

Original Expiration Date<sup>1</sup>:

December 9, 2003

Applicant:

Klaus Grohe, et al.

Owner of Record:

Bayer Aktiengesellschaft

Title:

7-Amino-1-Cyclopropyl-4-Oxo-1,4-Dihydro-Quinoline-and Naphthyridine-3-Carboxylic Acids and Antibacterial Agents Containing These

Compounds

Classification:

514/300

Product Trade Name:

BAYTRIL® (enrofloxacin)

Term Extended:

Three years

Expiration Date of Extension:

December 9, 2007

<sup>&</sup>lt;sup>1</sup>Subject to the provisions of 35 U.S.C. § 41(b).

Any correspondence with respect to this matter should be addressed as follows:

By mail:

**Assistant Commissioner for Patents** 

Box Patent Ext.

Washington, D.C. 20231

By FAX:

(703) 308-6916

Attn: Special Program Law Office

By hand:

One Crystal Park, Suite 520

2011 Crystal Drive Arlington, VA

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.

Karin Tyson

Senior Legal Advisor

Special Program Law Office

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

cc: Ron

Ronald L. Wilson, Director Health Assessment Policy Staff Office of Health Affairs (HFY-20) Food and Drug Administration 5600 Fishers Lane, Room 15-22 Rockville, MD 20857 RE: BAYTRIL®

FDA Docket No.: 96E-0504